EUR/USD
1.15757
0.056%
Gold
4166.25
0.860%
Oil
57.864
-0.260%
USD/JPY
156.362
0.187%
GBP/USD
1.31774
0.100%
GBP/JPY
206.049
0.293%
Real-time News
Novo Nordisk shares rose 1.4% after the U.S. cut healthcare spending on 15 expensive drugs by 36%.November 26th - According to the latest survey by TrendForce, in the third quarter of 2025, DRAM industry revenue increased by 30.9% compared to the previous quarter, reaching US$41.4 billion. This was driven by rising contract prices for conventional DRAM, increased shipments, and expanded shipments of high-bandwidth memory (HBM) chips. Looking ahead to the fourth quarter, TrendForce predicts that the final contract price for conventional DRAM will increase by 45-50% quarter-on-quarter, and the overall contract price for conventional DRAM and HBM combined will also increase by 50-55%.On November 26th, Teslas stock price initially declined before recovering on Tuesday. The stock briefly dipped to $405.95 before closing at $419.40, a slight increase of 0.4%. The S&P 500 and Dow Jones Industrial Average rose 0.9% and 1.4%, respectively. Considering Teslas stock price surged 6.2% on Monday, Tuesdays gains were relatively modest. Optimism surrounding the prospects of autonomous driving provided some support for the stock price. Rob Wertheimer, an analyst at Melius Research, pointed out that Teslas FSD technology is iterating rapidly, further widening the gap with traditional automakers. "In the past decade, and even a year or two ago, we assumed other automakers could catch up quickly, but now we are less certain. We have to think about chips, vertical integration, software capabilities, and whether we are truly looking at the car itself from a completely new perspective. Traditional automakers strategies and operations may be overly focused on cost control." Wertheimer remains bullish on the disruptive potential of autonomous vehicles, giving Tesla a "buy" rating with a target price of $525. According to FactSet data, 41% of analysts covering Tesla currently have a "buy" rating, compared to an average of about 55% for S&P 500 stocks.After the U.S. cuts 36% of healthcare spending on 15 drugs, GlaxoSmithKline and AstraZeneca opened roughly flat in European markets.On Wednesday, November 26, the German DAX 30 index opened 128.54 points higher, or 0.55%, at 23,588.62; the UK FTSE 100 index opened 18.24 points higher, or 0.19%, at 9,627.77; and the French CAC 40 index opened 45.01 points higher, or 0.56%, at 8,070.81. The Stoxx 50 index opened 36.39 points higher, or 0.65%, at 5610.30 on Wednesday, November 26; the Spanish IBEX 35 index opened 41.44 points higher, or 0.26%, at 16182.34 on Wednesday, November 26; and the Italian FTSE MIB index opened 174.34 points higher, or 0.41%, at 42873.00 on Wednesday, November 26.
